DelveInsight’s “Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Allergic Rhinitis, historical and forecasted epidemiology, as well as the Allergic Rhinitis market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Discover Key Insights into the Allergic Rhinitis Market with DelveInsight’s In-Depth Report @ Allergic Rhinitis Market Size
Key Takeaways from the Allergic Rhinitis Market Report
The leading Allergic Rhinitis companies include Regeneron Pharmaceuticals, Glenmark Pharmaceuticals, Allergy Therapeutics, ALK-Abello, GSK, and others.
Rising prevalence of allergic diseases globally is driving demand for advanced immunotherapies offering effective symptom management and improved quality of life.
Breakthroughs in monoclonal antibody therapies, intranasal combinations, and allergen-specific immunotherapies are expanding treatment options and clinical efficacy.
The Allergic Rhinitis market in the 7MM is expected to witness major growth during the study period 2020–2034.
Key therapeutic targets include monoclonal antibodies against allergen-specific molecules, intranasal corticosteroids, and novel combination therapies.
Stay ahead in the Allergic Rhinitis Market with DelveInsight’s Strategic Report @ Allergic Rhinitis Market Outlook
Allergic Rhinitis Epidemiology Segmentation in the 7MM
Total Allergic Rhinitis Patient Population
Market Size by Geographic Region
Market Size by Allergen Type
Allergic Rhinitis Treatment Market
Allergic Rhinitis Pipeline Analysis
Allergic Rhinitis Market Size
In 2023, the Allergic Rhinitis Market Size in the 7MM was approximately USD 10,400 million, which is expected to increase significantly by 2034. The United States accounted for the highest market share at approximately USD 3,600 million in 2023, representing 34% of the total 7MM market. Among EU countries, Germany had the highest market size with USD 1,358 million, while Japan contributed USD 2,347 million, accounting for 23% of the total market.
RYALTRIS (Olopatadine Hydrochloride and Mometasone Furoate): Glenmark Pharmaceuticals
RYALTRIS is a metered, fixed-dose, aqueous suspension nasal spray combining a histamine H1-receptor inhibitor and a corticosteroid. Approved by the FDA in January 2022 for treating seasonal allergic rhinitis symptoms in adults and pediatric patients 12 years and older, RYALTRIS represents a significant advancement in combination therapy. In August 2021, it received marketing approval in 13 European Union countries and the UK, establishing itself as a key therapeutic option in the allergic rhinitis treatment landscape.
REGN5713-5714-5715: Regeneron Pharmaceuticals
REGN5713-5714-5715 is an investigational combination of three fully human monoclonal antibodies designed to target Bet v1, the primary allergen responsible for birch pollen allergies. These antibodies were developed using Regeneron’s proprietary VelocImmune platform. Preclinical studies demonstrate that the three antibodies bind independently and non-competitively to Bet v1, providing maximal inhibition of allergen binding to human polyclonal IgE and effectively blocking basophil activation and mast cell degradation. The therapy is expected to launch in EU4 and the UK by 2025, and in Japan by 2026. Currently in Phase III development, it is anticipated to achieve market entry with a slow-to-medium uptake profile.
Grass MATA MPL: Allergy Therapeutics
Grass MATA MPL is a pre-seasonal subcutaneous immunotherapy developed from an extract of 13 grass pollens modified with glutaraldehyde to form allergoids. These allergoids reduce reactivity with IgE antibodies while preserving T-cell reactivity. The formulation includes monophosphoryl lipid-A (MPL) as an adjuvant to enhance immunogenicity and promote the shift from Th2 to Th1 immune responses. In November 2023, Allergy Therapeutics completed Phase III studies evaluating efficacy and safety in subjects with seasonal allergic rhinitis and rhinoconjunctivitis induced by grass pollen.
Allergic Rhinitis Market Insights
The current treatment landscape includes allergen avoidance, pharmacotherapy (antihistamines, intranasal corticosteroids, decongestants), and allergen-specific immunotherapy. Intranasal corticosteroids (INSs) are recognized as the most effective first-line treatment for moderate/severe persistent allergic rhinitis. The competitive landscape is highly dynamic, with leading players advancing fixed-dose combinations, novel immunotherapies, and targeted biological agents. The expected introduction of emerging therapies with improved efficacy and greater awareness initiatives are likely to boost market growth across the 7MM.
Allergic Rhinitis Epidemiology
In 2023, estimated total diagnosed prevalent cases of allergic rhinitis in the 7MM were approximately 90 million. Japan had the highest diagnosed prevalent cases at approximately 26 million (30% of 7MM total), followed by Germany (~10 million), the United Kingdom (~9 million), and Spain (~5 million). Approximately 20% of cases were mild, 60% moderate, and 20% severe. The 18–59 years age group had the highest burden (~60 million cases). Grass pollen was the leading allergen trigger, followed by tree pollen, dust mites, weed pollen, animal dander, and fungal spores.
Get In-Depth Knowledge on Allergic Rhinitis Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/report-store/allergic-rhinitis-market
Allergic Rhinitis Market Outlook
The primary treatment goal is symptom relief and improved quality of life. Therapeutic options include allergen avoidance, nasal saline irrigation, oral antihistamines, intranasal corticosteroids, combination intranasal therapies, leukotriene receptor antagonists (LTRAs), and allergen immunotherapy. With the expected launch of REGN5713-5714-5715 and other pipeline agents, the total Allergic Rhinitis Market Size is expected to showcase significant growth through 2034.
Scope of the Allergic Rhinitis Market Report
Coverage: 7MM
Study Period: 2020–2034
Forecast Period: 2024–2034
Allergic Rhinitis Companies: Regeneron Pharmaceuticals, Glenmark Pharmaceuticals, Allergy Therapeutics, ALK-Abello, HAL Allergy Ltd., and others
Allergic Rhinitis Therapies: RYALTRIS, REGN5713-5714-5715, Grass MATA MPL, GRASTEK/GRAZAX, ODACTRA/ACARIZAX, and others
Unlock Strategic Insights with DelveInsight’s Comprehensive Allergic Rhinitis Market Report @ Allergic Rhinitis Market Drivers and Barriers
Table of Contents
1 Key Insights
2 Report Introduction
3 Allergic Rhinitis Market Overview at a Glance
3.1 Market Share (%) Distribution of Allergic Rhinitis in 2020
3.2 Market Share (%) Distribution of Allergic Rhinitis in 2034
4 Epidemiology and Market Forecast Methodology
5 Key Events
6 Executive Summary of Allergic Rhinitis
7 Disease Background and Overview of Allergic Rhinitis
7.1 Introduction
7.2 Classification of Rhinitis
7.3 Etiology
7.4 Pathogenesis
7.5 Signs and Symptoms
7.6 Complications of Allergic Rhinitis
7.7 Diagnosis
7.7.1 Differential Diagnosis
7.7.2 Diagnostic Guidelines
7.7.2.1 Allergic Rhinitis: Clinical Practice Guideline by American Academy of Otolaryngology-Head and Neck Surgery (Endorsed 2014, Reaffirmed April 2020)
7.7.2.2 Consensus Statement of the Italian Society of Pediatric Allergy and Immunology for the Pragmatic Management of Children and Adolescents With Allergic or Immunological Diseases During the COVID-19 Pandemic: 2020
7.7.2.3 Recommendation for Clinical Practice Diagnostic and Therapeutic Management of Allergic Rhinitis by ENT: French Society of Oto-Rhino-Laryngology and Face and Neck Surgery, 2020
7.7.2.4 Japanese Guidelines for Allergic Rhinitis: 2020
7.8 Treatment
7.8.1 Treatment Guidelines
7.8.1.1 Allergic Rhinitis: Clinical Practice Guideline by American Academy of Otolaryngology Head and Neck Surgery (Endorsed 2014, Reaffirmed April 2020)
7.8.1.2 ARIA Guideline 2019: Treatment of Allergic Rhinitis in the German Health System
7.8.1.3 British Society of Allergy and Clinical Immunology (BSACI) Guideline for the Diagnosis and Management of Allergic and Non-allergic Rhinitis (Revised Edition 2017)
7.8.1.4 Consensus Statement of the Italian Society of Pediatric Allergy and Immunology for the Pragmatic Management of Children and Adolescents With Allergic or Immunological Diseases During the COVID-19 Pandemic: 2020
7.8.1.5 Recommendation for Clinical Practice Diagnostic and Therapeutic Management of Allergic Rhinitis by ENT: French Society of Oto-Rhino-Laryngology and Face and Neck Surgery, 2020
7.8.1.6 Japanese Guidelines for Allergic Rhinitis: 2020
8 Epidemiology and Patient Population of Allergic Rhinitis
8.1 Key Findings
8.2 Assumptions and Rationale: The 7MM
8.3 Total Prevalent Cases of Allergic Rhinitis in the 7MM
8.4 Diagnosed Prevalent Cases of Allergic Rhinitis in the 7MM
8.5 The United States
8.6 EU4 and the UK
8.7 Japan
9 Patient Journey
10 Marketed Drugs
10.1 Key Cross
10.2 RYALTRIS (Olopatadine Hydrochloride and Mometasone Furoate Monohydrate Nasal Spray): Glenmark Pharmaceuticals Inc.
11 Emerging Drugs
11.1 Key Cross Competition
11.2 REGN5713-5714-5715: Regeneron Pharmaceuticals
11.3 Grass MATA MPL: Allergy Therapeutics
12 Allergic Rhinitis: Seven Major Market Analysis
12.1 Key Findings
12.2 Market Outlook
12.3 Key Market Forecast Assumptions
12.4 Conjoint Analysis
12.5 Total Market Size of Allergic Rhinitis in the 7MM
12.6 Market Size of Allergic Rhinitis by Therapies in the 7MM
12.7 Market Size of Allergic Rhinitis in the United States
12.8 Market Size of Allergic Rhinitis in EU4 and the UK
12.9 Market Size of Allergic Rhinitis in Japan
13 Key Opinion Leaders’ Views
14 SWOT Analysis
15 Unmet Needs
16 Market Access and Reimbursement
16.1 The United States
16.2 EU4 and the UK
16.3 Japan
17 Appendix
17.1 Bibliography
17.2 Acronyms and Abbreviations
17.3 Report Methodology
18 DelveInsight Capabilities
19 Disclaimer
Related Reports
Allergic Rhinitis – Pipeline Insight, 2026
DelveInsight’s, “Allergic Rhinitis – Pipeline Insight, 2026,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in the Allergic Rhinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kanishk KumarEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/report-store/allergic-rhinitis-market
